Streetbeat News

Regulatory

MSFT

SPY

Italy's Data Protection Authority plans to review other artificial intelligence platforms after temporarily banning ChatGPT in March. This move could potentially impact companies like Microsoft (MSFT) and the S&P 500 ETF (SPY).

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:09 pm

SPY

Federal Reserve's Bullard warns that if inflation is not controlled, the Fed will have to 'do a lot more' and should err on the side of doing more, according to Reuters.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:05 pm

CS

Credit Suisse employees are preparing to sue Swiss regulator FINMA after losing $400 million in bonuses tied to the bank's AT1 bonds due to the UBS takeover. Law firms Quinn Emanuel and Pallas have received requests from senior managers at Credit Suisse to take legal action on their behalf.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 1:05 pm

ICPT

Intercept Pharmaceutical's Ocaliva 25 mg, a drug for nonalcoholic steatohepatitis (NASH) patients, faced a setback as the FDA's Gastrointestinal Drugs Advisory Committee voted against its benefits, stating they don't outweigh the risks. The FDA highlighted an increased risk of diabetes and liver injury from using OCA oral tablets to treat NASH.

Portfolio Pulse from Vandana Singh

May 22, 2023 | 1:01 pm

SPY

Federal Reserve Bank of St. Louis President James Bullard stated that the Fed may need to raise the policy rate by an additional 50 basis points this year to combat inflation while the labor market remains strong.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 1:01 pm

SPY

St. Louis Fed's Bullard states that the base case remains relatively slow growth for the rest of this year and into 2024, and recession probabilities are 'overstated'.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:59 pm

MBOT

Microbot Medical's LIBERTY Surgical Robotic System achieved a 100% success rate in an extended pre-clinical animal study conducted by leading European physicians. The system was found to be intuitive and easy to use, with positive feedback from interventional radiologists. The company plans to enter the human clinical phase in the second half of the year.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:56 pm

CMND

Clearmind Medicine has announced its first US site for a Phase I/IIa clinical trial evaluating CMND-100 in patients with alcohol use disorder.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:54 pm

AKBA

Akebia Therapeutics (NASDAQ: AKBA) has received UK MHRA approval for Vafseo, an oral treatment for symptomatic anemia associated with chronic kidney disease in adults on chronic maintenance dialysis. The approval is based on data from a comprehensive development program, including the global Phase 3 clinical program of vadadustat.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2023 | 12:54 pm

CGC

Canopy Growth Corporation has filed a revised proxy statement with the SEC, modifying the structure of Canopy USA to comply with NASDAQ listing requirements. The changes include reducing Canopy Growth's economic interest in Canopy USA to no greater than 90% and adjustments to the board of managers. Shareholders will be asked to consider a special resolution authorizing the creation of a new class of non-voting exchangeable shares.

Portfolio Pulse from Vuk Zdinjak

May 22, 2023 | 12:51 pm